According to Evolent Health's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.86052. At the end of 2023 the company had a P/S ratio of 2.09.
Year | P/S ratio | Change |
---|---|---|
2023 | 2.09 | -0.46% |
2022 | 2.10 | -22.87% |
2021 | 2.72 | 106.02% |
2020 | 1.32 | 46.23% |
2019 | 0.9045 | -64.09% |
2018 | 2.52 | 19.26% |
2017 | 2.11 | -31.01% |
2016 | 3.06 | -18.41% |
2015 | 3.75 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() National Healthcare
NHC | 0.9133 | -50.91% | ๐บ๐ธ USA |
![]() Global Cord Blood CORBF | 0.8635 | -53.59% | ๐ญ๐ฐ Hong Kong |
![]() Graham Holdings GHC | 0.6343 | -65.91% | ๐บ๐ธ USA |
![]() CryoLife CRY | N/A | N/A | ๐บ๐ธ USA |